Filing Flows

Filing Flows › Health Care › Champions Oncology (CSBR)

Champions Oncology (CSBR) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Sep 11, 2026 · Champions Oncology (CSBR) Q1 FY27 earnings results →

Q1 FY27 Revenue up 9% year over year to $15.2M · 3¢ of every $1 of revenue lost · operating margin -2.7%

Champions Oncology made $15.2M in Q1 FY27 (+9% Y/Y): Pharmacology services $14.2M, TOS data license revenue $893K, Other TOS revenue $183K. Operating margin -2.7%, net loss $426K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 11, 2026.

Revenue$15.2M
Year over year+9%
Operating margin-2.7%
Net earnings−$426K
Operating cash flow−$492K

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $15.2M in Q1 FY27, up 9% year over year and up 10% from the previous quarter. Pharmacology services was the largest line at 93% of revenue. Pharmacology services added $926K year over year (up 7%), 75% of the total change. Other TOS revenue declined 60%.

Operating costs exceeded revenue by $409K, an operating margin of -2.7%. Total costs grew 8% against revenue growth of 9%. The fastest-growing cost line was Sales & marketing (+67%). The quarter ended with a net loss of $426K, narrower than the previous quarter's $667K loss.

Operating cash flow was −$492K. Non-cash charges added back $314K of depreciation and amortization and $766K of share-based compensation. Working capital and other items used $1.1M. Capital expenditures of $55K exceeded it, leaving free cash flow of −$547K.

Quarterly history

Champions Oncology revenue by quarterChampions Oncology revenue by quarter$17.0MQ3 FY25$12.4MQ4 FY25$14.0MQ1 FY26$15.0MQ2 FY26$16.6MQ3 FY26$13.8MQ4 FY26$15.2MQ1 FY27
Champions Oncology net earnings by quarterChampions Oncology net earnings by quarter$4.5MQ3 FY25−$1.8MQ4 FY25−$466KQ1 FY26$268KQ2 FY26−$278KQ3 FY26−$667KQ4 FY26−$426KQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QSep 11, 2026$15.2M+9%-2.7%−$426K−$492K
Q4 FY2610-KJul 27, 2026$13.8M+12%-3.8%−$667K−$2.0M
Q3 FY2610-QMar 12, 2026$16.6M-3%-1.7%−$278K−$1.3M
Q2 FY2610-QDec 15, 2025$15.0M+12%1.2%$268K−$1.7M
Q1 FY2610-QSep 15, 2025$14.0M-0.5%-3.8%−$466K$600K
Q4 FY2510-KJul 23, 2025$12.4M-12%-16.2%−$1.8M$6.9M
Q3 FY2510-QMar 17, 2025$17.0M+42%26.4%$4.5M$490K

Charts

Champions Oncology: revenue growth, year over year and quarter over quarterChampions Oncology: revenue growth, year over year and quarter over quarterY/YQ/Q+42%Q3 FY25-12%-27%Q4 FY250%+13%Q1 FY26+12%+7%Q2 FY26-3%+10%Q3 FY26+12%-16%Q4 FY26+9%+10%Q1 FY27
Latest (Q1 FY27): Y/Y +9%, Q/Q +10%.
Champions Oncology: where the cash came from (+) and went (−), TTM to Q1 FY27Champions Oncology: where the cash came from (+) and went (−), TTM to Q1 FY27Cash drawn (+) / kept (−)$6.0MOperating cash flow−$5.6MCapital spending−$573KShares issued$262KNet borrowing (+) / repaid (−)−$116KOther investing$24K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Champions Oncology: profit against cash, quarter by quarterChampions Oncology: profit against cash, quarter by quarterNet incomeOperating cash flow$728K−$283KQ2 FY25$4.5M$490KQ3 FY25−$1.8M$6.9MQ4 FY25−$466K$600KQ1 FY26$237K−$1.7MQ2 FY26−$278K−$1.3MQ3 FY26−$667K−$2.0MQ4 FY26−$426K−$492KQ1 FY27
Latest (Q1 FY27): Net income −$426K, Operating cash flow −$492K.
Champions Oncology: diluted shares by fiscal yearChampions Oncology: diluted shares by fiscal year15MFY2114MFY2214MFY2314MFY2414MFY2514MFY26
-5.1% since FY21: buybacks shrank the count.
Champions Oncology in its industry: growth against margin (76 companies, SIC 2836)Champions Oncology in its industry: growth against margin (76 companies, SIC 2836)revenue growth, year over year →↑ operating marginmedian +9%median -100%AMGNGILDBIIBMRNANBIXEXELHALOMGTXTECHVIRRGENTARSBCRXALECADMAKRYSIOVATWSTIPSCIMCRVISKVCELADPTNVAXKYMRGLUEIBRXAUTLAGENDNAPLXRXRXFENCCHRSIVVDCRSPEDITDTILVXRTSTRORGNXCCCCBSEMSCLXACOGTSHASRZNVYGRFDMTLENZALGSXFORELUTFATEOCGNSCTXCRBUCGONDBVTINBXMGXLCTXTCRXDYAIPRMEATRAVitro Biopharma, Inc.HUMARLAYPLURBEAMPROKCRDFAIMVIVSCSBR (+9%, -3%)
Biological Products, (No Diagnostic Substances); dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Champions Oncology

We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs.

In its own words, from its annual report, filed Jul 23, 2025.

Champions Oncology against its Biological Products, (No Diagnostic Substances) peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +11%. Operating margin: -2.7% against the peers' median 35.8%.

CompanyQuarterRevenueY/YOp. margin
CSBR Champions OncologyQ1 FY27$15.2M+9%-2.7%
AMGN AmgenQ3 2026$10.4B+8%35.8%
GILD Gilead SciencesQ3 2026$8.3B+7%41.7%
BIIB BiogenQ3 2026$2.8B+11%-0.3%
MRNA ModernaQ3 2026$1.3B+29%9.9%
NBIX Neurocrine BiosciencesQ3 2026$1.1B+41%29.5%
EXEL ExelixisQ3 2026$659M+10%40.8%
HALO Halozyme TherapeuticsQ3 2026$493M+39%59.8%
MGTX MeiraGTx HoldingsQ2 2026$321M87×76.0%

Source: Champions Oncology 10-Q on SEC EDGAR · CIK 771856 · Biological Products, (No Diagnostic Substances)

13F: who owns CSBR and who is buying

Largest holders of CSBR (13F)Largest holders of CSBR (13F)Battery Management$14.9MNEA Management Company, LLC$10.6MVanguard Group$2.3MVanguard Capital Management LLC$1.9MTocqueville Asset Management L.P.$1.8MMorgan Stanley$1.5MBank of America$1.3MRenaissance Technologies LLC$856KBlackRock$800KMink Brook Asset Management LLC$686K
Funds' net buying of CSBR by quarter (13F)Funds' net buying of CSBR by quarter (13F)$59K2024-09$291K2024-12$1.7M2025-03−$1.0M2025-06−$760K2025-09$174K2025-12−$106K2026-03$1.0M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on CSBR

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare CSBR with

中文版：Champions Oncology（CSBR）财报

Español · Français